Evaluating blood biomarkers in advanced thyroid cancer
Evaluation of the Clinical Utility of Circulating Biomarkers in Advanced Thyroid Carcinomas
This study is testing if analyzing blood samples from adults with advanced thyroid cancer can help doctors choose better treatments and track how well they work.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Locations | 1 site (Bologna) |
| Trial ID | NCT06863805 on ClinicalTrials.gov |
What this trial studies
This study focuses on adult patients diagnosed with advanced thyroid carcinomas, particularly those who are candidates for systemic therapy. It utilizes liquid biopsy techniques to analyze circulating DNA, RNA, and tumor cells from blood samples, aiming to create a molecular profile that can guide treatment decisions. By comparing these profiles to traditional genomic sequencing from tumor tissue, the study seeks to enhance patient selection for therapies and monitor treatment responses. The research highlights the potential of noninvasive methods to improve the management of thyroid cancer.
Who should consider this trial
Good fit: Ideal candidates are adults with advanced thyroid carcinomas who are eligible for systemic therapy and have available tumor tissue for molecular profiling.
Not a fit: Patients who are already receiving systemic therapy or are not eligible for such treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for patients with advanced thyroid cancer.
How similar studies have performed: Other studies have shown promise in using liquid biopsy techniques for various cancers, indicating potential success for this approach in thyroid cancer as well.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Signed written informed consent, * Adult (≥18 years) male or female patients * Histologic diagnosis of advanced thyroid carcinoma confirmed at centralized review, * well-differentiated thyroid carcinomas, medullary thyroid carcinomas, anaplastic thyroid carcinomas, advanced, candidates for initiation of systemic medical therapy, * Availability of biomolecular profiling performed by multigenic NGS panel on tumor tissue, * Measurable disease by conventional imaging adopted in clinical practice (total body CT with mdc, CT-PET with FDG or F-DOPA). Exclusion Criteria: * Patients already receiving previous lines of systemic therapy, * Patients not eligible for systemic therapy.
Where this trial is running
Bologna
- IRCCS Azienda Ospedaliero universitaria Bologna — Bologna, Italy (Recruiting)
Study contacts
- Study coordinator: Margherita Nannini
- Email: margherita.nannini@unibo.it
- Phone: +390512142207
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.